Generic Oncology Drugs Market Size & Share 2024 – 2032

Generic Oncology Drugs Market Size

Generic Oncology Drugs Market was valued at USD 26.9 billion in 2023 and is estimated to grow at 5.8% CAGR from 2024 to 2032, attributed to the global rise in cancer cases along with factors such as aging demographics, shifts in lifestyle, and environmental influences. According to the latest projections from the World Health Organization's cancer agency, there is an anticipated 77% surge in new cancer cases by 2050, totaling over 35 million cases, compared to the estimated 20 million cases recorded in 2022.

Generic oncology drugs replicate the active pharmaceutical ingredients of branded cancer drugs, providing similar therapeutic outcomes. These drugs are developed post-patent expiry, with rigorous regulatory evaluation to ensure safety, efficacy, and bioequivalence. The generics offer affordable options for treating diverse cancer types, broadening patient access to essential treatments.
 

Generic Oncology Drugs Market Trends

The substantial costs associated with cancer diagnostics and treatments are a major contributor to the global economic strain, coupled with the limited treatment accessibility and high mortality rates. This has surged the demand for affordable treatment options, driving the acceptance of generics and spurring market growth. Also, to meet the global demand, pharmaceutical companies are actively focusing on continuous research and development activities to offer cost-effective cancer treatments.
 

• For instance, in 2020, Zydus Cadila introduced 'Obnyx,' a generic Enzalutamide capsule offering weekly therapy for prostate cancer. It slashes monthly treatment costs by 70%, significantly lower than existing options in India. The launch aimed to provide affordable treatment, promoting treatment adherence for prostate cancer patients.
   

Therefore, the affordability factor, coupled with rising cancer prevalence, enhanced the significance of generic options in addressing the global burden of cancer care, thereby augmenting the market growth.
 

Generic Oncology Drugs Market Analysis

Based on drug type, the market is categorized into chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, hormonal therapy drugs, and other drug types. The targeted drugs segment is projections to reach USD 16.1 billion by 2032.
 

• Targeted therapy in oncology differs from traditional chemotherapy by precisely targeting cancer cells, minimizing harm to healthy tissue, and reducing side effects. Its efficacy and improved patient outcomes have led to widespread adoption, among patients. For instance, research indicated that targeted therapy could achieve up to an impressive 80% effectiveness rate, significantly higher than the approximately 30% success rate typically associated with traditional chemotherapy courses. This stark contrast underscores the superior efficacy of targeted therapy in treating cancer, further emphasizing its growing prominence as a preferred treatment option in oncology.
   
• Thus, the aforementioned factors witness that targeted therapy has become the preferred option, revolutionizing the approach to generic oncology treatment which in turn spur the market growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on indication, the generic oncology drugs market is classified into prostate cancer, lung cancer, breast cancer, colorectal cancer, leukemia, and other indications. The breast cancer segment holds the largest market share of 31.5% in 2023.
 

• Within the realm of breast cancer treatment, a variety of generic drugs are extensively utilized across different stages of the disease. Chemotherapy remains a cornerstone of treatment, with generic agents such as paclitaxel, docetaxel, doxorubicin, cyclophosphamide, and gemcitabine commonly employed either alone or in combination regimens. These drugs are administered in neoadjuvant or adjuvant settings to reduce tumor size before surgery or to target residual disease post-surgery.
   
• Additionally, in the management of advanced or metastatic breast cancer, generic chemotherapy agents continue to play a vital role in controlling disease progression.
   
• Thus, the availability of cost-effective generic options enhances treatment accessibility, particularly in resource-limited settings, thereby contributing significantly to the overall management of breast cancer on a global scale.
   

Based on the route of administration, the generic oncology drugs market is segmented into oral, topical, and injectable. The injectable segment accounted for the largest share in the market and is expected to exhibit 5.6% CAGR through 2032.
 

• Injectable medications are often preferred in oncology for their ability to deliver precise doses directly into the bloodstream, ensuring rapid and effective distribution of the drug throughout the body. Within this segment, a wide range of generic injectable oncology drugs are available, offering cost-effective alternatives to brand-name medications.
   
• Further, generic versions of monoclonal antibodies, such as trastuzumab and bevacizumab, are frequently administered intravenously to target specific molecular pathways involved in cancer growth and progression. Thus, their versatility in administration routes and formulations further solidified their position as the leading segment in the market.
   

Based on the end-user, the generic oncology drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is likely to exceed USD 20.4 billion by 2032.
 

• As key stakeholders in the global market, hospital pharmacies are responsible for procuring, storing, compounding, and dispensing a wide range of generic medications used in cancer treatment. With a focus on patient safety and medication management, hospital pharmacists ensure the appropriate selection and dosage of generic oncology drugs based on patient-specific factors such as disease stage, treatment regimen, and comorbidities.
   
• Additionally, hospital pharmacies are actively involved in promoting cost-effective medication utilization through the adoption of generic alternatives to brand-name oncology drugs. By incorporating generic options into formularies and treatment protocols, hospital pharmacies contribute to cost containment efforts while maintaining high standards of care for cancer patients.
   
• Such aforementioned factors are expected to supplement the market growth.
   

U.S. dominated the North American generic oncology drugs market accounting for USD 11.3 billion in 2023.
 

• The U.S. market experiences growth due to factors such as increasing cancer cases, rising adoption of branded generics, expanding healthcare spending, widespread cancer screening, availability of innovative treatments, and a strong presence of leading generic drug manufacturers.
   
• Cancer diagnoses in the U.S. are projected to continue rising. For instance, according to the American Cancer Society estimates 1.9 million new cases and 609,360 deaths in 2022. This aimed to surge the demand for oncology drugs Consequently, demand for generic oncology drugs is expected to surge throughout the forecast period.


• Moreover, increased research and development investment, the rapid expansion of cancer-supportive care drugs and other products, coupled with the a rise in new drug approvals will further bolster the country's generic oncology drug market share in the coming years.
   

Germany exhibited a high growth potential in the European generic oncology drugs market.
 

• Germany, as the hub of the European pharmaceutical market, hosts numerous industry leaders and a burgeoning biotech sector, supported by a robust public healthcare system.
   
• Also, the demographic shifts, such as the aging population, will drive demand for pharmaceuticals, particularly for chronic diseases like cancer. This trend favored the producers of niche products and encouraged investment in oncology drugs, including generics. Thus, such factors will foster the country level market growth.
   

The Asia Pacific generic oncology drugs market is poised to attain gains at nearly 6% up to 2032.
 

• The Asia-Pacific region is set to experience significant expansion in the generic oncology drugs industry, propelled by rapid urbanization, enhanced healthcare infrastructure, and a growing incidence of cancer.
   
• Moreover, supportive government policies aimed at fostering affordable medication costs and enhancing the availability of generic drugs contribute to market growth.
   
• India is a key contributor to the Asia Pacific market, leveraging its cost-effective manufacturing capabilities. The government policies and initiatives promoting the use of affordable generic medications, facilitated market expansion. For instance, an amendment to the code of conduct for doctors by the Medical Council of India mandated the prescription of medications using legible generic names. This emphasized the significance of rational prescriptions, promoting the use of generic drugs.
   
• Thus, escalating government initiatives and support for affordable treatments are anticipated to fuel the demand for generic oncology drugs in the regional and country level market.
   

Generic Oncology Drugs Market Share

The generic oncology drugs industry comprises intense competition driven by numerous players offering cost-effective alternatives to branded medications. Key factors influencing competition include pricing strategies, product quality, regulatory compliance, and distribution networks. In addition, the companies are continually focusing on innovation in manufacturing processes and strategic partnerships which are pivotal for sustaining competitiveness in this dynamic market landscape.
 

Generic Oncology Drugs Market Companies

Some of the prominent players operating in the generic oncology drugs industry include:

• AbbVie Inc.
• Apotex Inc.
• AstraZeneca
• Biocon Ltd.
• Gland Pharma Limited
• Incyte Corporation
• Lupin Pharmaceuticals, Inc.
• Mylan N.V. 
• Natco Pharma Ltd.
• Novartis Pharmaceuticals Corporation
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Synthon Pharmaceuticals, Inc.
• Teva Pharmaceuticals
• Zydus Lifesciences Limited
   

Generic Oncology Drugs Market News

• In April 2024, Gland Pharma received the U.S. Food and Drug Administration (FDA) approval to commercialize a generic version of Eribulin Mesylate Injection, for the treatment of breast cancer. This approval aimed to introduce a new cost-effective alternative to cancer therapy. This strategy is expected to enhance their product offerings.
   
• In March 2024, Zydus introduced IBYRA, the generic version of Olaparib- a PARP inhibitor in India. This drug aims to target the specific genetic mutations associated with certain types of cancers. The launch of IBYRA, aimed to provide advanced therapeutic options tailored to their individual needs most affordably. This strategy is anticipated to add value to its existing portfolio.
   

This generic oncology drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Chemotherapy drugs
• Targeted therapy drugs
• Immunotherapy drugs
• Hormonal therapy drugs
• Other drug types

Market, By Indication

• Prostate cancer
• Lung cancer
• Breast cancer
• Colorectal cancer
• Leukemia
• Other indications

Market, By Route of Administration

• Oral
• Topical
• Injectable

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa